Search Results - "Fahmi, Odette A."

In Vitro Evaluation of the Potential for Drug Interactions by Salidroside by Kasprzyk, Philip G., Tremaine, Larry, Fahmi, Odette A., Weng, Jing-Ke

“…Several studies utilizing Rhodiola rosea, which contains a complex mixture of phytochemicals, reported some positive drug-drug interaction (DDI) findings based…”
Get full text

A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro by FAHMI, Odette A, MAURER, Tristan S, KISH, Mary, CARDENAS, Edwin, BOLDT, Sherri, NETTLETON, David

“…Although approaches to the prediction of drug-drug interactions (DDIs) arising via time-dependent inactivation have recently been developed, such approaches do…”
Get full text

Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes by Fahmi, Odette A, Kish, Mary, Boldt, Sherri, Obach, R Scott

“…Induction of cytochrome P450 (P450) activity in the clinic can result in therapeutic failure such as tissue rejection in transplant patients or unwanted…”
Get full text

Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction by Fahmi, Odette A, Hurst, Susan, Plowchalk, David, Cook, Jack, Guo, Feng, Youdim, Kuresh, Dickins, Maurice, Phipps, Alex, Darekar, Amanda, Hyland, Ruth, Obach, R Scott

“…Cytochrome P450 3A4 (CYP3A4) is the most important enzyme in drug metabolism and because it is the most frequent target for pharmacokinetic drug-drug…”
Get full text

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control by Hariparsad, Niresh, Ramsden, Diane, Palamanda, Jairam, Dekeyser, Joshua G, Fahmi, Odette A, Kenny, Jane R, Einolf, Heidi, Mohutsky, Michael, Pardon, Magalie, Siu, Y Amy, Chen, Liangfu, Sinz, Michael, Jones, Barry, Walsky, Robert, Dallas, Shannon, Balani, Suresh K, Zhang, George, Buckley, David, Tweedie, Donald

“…The European Medicines Agency (EMA), the Pharmaceutical and Medical Devices Agency (PMDA), and the Food and Drug Administration (FDA) have issued guidelines…”
Get full text

Evaluation of models for predicting drug-drug interactions due to induction by Fahmi, Odette A, Ripp, Sharon L

“…Drug-drug interactions caused by induction of metabolizing enzymes, particularly CYP3A, can impact the efficacy and safety of co-administered drugs. It is,…”
Get more information

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism by Gandelman, Kuan, Zhu, Tong, Fahmi, Odette A., Glue, Paul, Lian, Kenny, Obach, R. Scott, Damle, Bharat

“…The effect of rifampin on the steady‐state pharmacokinetics of linezolid was evaluated in an open‐label, multiple‐dose, crossover study in 16 healthy subjects…”
Get full text

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome by Dong, Jennifer Q, Gosset, James R, Fahmi, Odette A, Lin, Zhiwu, Chabot, Jeffrey R, Terra, Steven G, Le, Vu, Chidsey, Kristin, Nouri, Parya, Kim, Albert, Buckbinder, Leonard, Kalgutkar, Amit S

“…The propensity for CYP3A4 induction by 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2 )-yl)acetamide (PF-06282999), an irreversible…”
Get full text

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin by Varma, Manthena V S, Lin, Jian, Bi, Yi-An, Rotter, Charles J, Fahmi, Odette A, Lam, Justine L, El-Kattan, Ayman F, Goosen, Theunis C, Lai, Yurong

“…Repaglinide is mainly metabolized by cytochrome P450 enzymes CYP2C8 and CYP3A4, and it is also a substrate to a hepatic uptake transporter, organic anion…”
Get full text

Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction by RIPP, Sharon L, MILLS, Jessica B, FAHMI, Odette A, TREVENA, Kristen A, LIRAS, Jennifer L, MAURER, Tristan S, DE MORAIS, Sonia M

“…Cytochrome P4503A4 (CYP3A4) is the principal drug-metabolizing enzyme in human liver. Drug-drug interactions (DDIs) caused by induction of CYP3A4 can result in…”
Get full text

A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells by Wakuda, Hirokazu, Nejime, Namie, Tada, Yukari, Kagota, Satomi, Fahmi, Odette A., Umegaki, Keizo, Yamada, Shizuo, Shinozuka, Kazumasa

“…Objectives  The aim of this study was to use time‐lapse confocal laser scanning microscopy to establish a more sensitive and specific method for evaluating…”
Get full text

Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions by Fahmi, Odette A.

Get full text

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective by Fahmi, Odette A, Shebley, Mohamad, Palamanda, Jairam, Sinz, Michael W, Ramsden, Diane, Einolf, Heidi J, Chen, Liangfu, Wang, Hongbing

“…Drug-drug interactions (DDIs) due to CYP2B6 induction have recently gained prominence and clinical induction risk assessment is recommended by regulatory…”
Get full text

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper by Evers, Raymond, Dallas, Shannon, Dickmann, Leslie J, Fahmi, Odette A, Kenny, Jane R, Kraynov, Eugenia, Nguyen, Theresa, Patel, Aarti H, Slatter, J Greg, Zhang, Lei

“…Drug-drug interactions (DDIs) between therapeutic proteins (TPs) and small-molecule drugs have recently drawn the attention of regulatory agencies, the…”
Get full text

PREDICTION OF DRUG-DRUG INTERACTIONS FROM IN VITRO INDUCTION DATA : Application of the Relative Induction Score Approach Using Cryopreserved Human Hepatocytes by FAHMI, Odette A, BOLDT, Sherri, KISH, Mary, OBACH, R. Scott, TREMAINE, Larry M

“…Cytochrome P450 induction-mediated drug-drug interaction (DDI) is one of the major concerns in clinical practice and for the pharmaceutical industry…”
Get full text

An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation by Chang, Cheng, Yang, Xin, Fahmi, Odette A., Riccardi, Keith A., Di, Li, Obach, R. Scott

“…1. Induction is an important mechanism contributing to drug-drug interactions. It is most commonly evaluated in the human hepatocyte assay over 48-h or 72-h…”
Get full text

Lack of effect of tofacitinib (CP‐690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data by Gupta, Pankaj, Alvey, Christine, Wang, Rong, Dowty, Martin E., Fahmi, Odette A., Walsky, Robert L., Riese, Richard J., Krishnaswami, Sriram

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Tofacitinib (CP‐690,550) is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator…”
Get full text

Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships by Fahmi, Odette A, Raucy, Judy L, Ponce, Elsa, Hassanali, Saleema, Lasker, Jerome M

“…The increase in cytochrome P450 (P450) enzyme activity noted upon exposure to therapeutics can elicit marked drug-drug interactions (DDIs) that may ultimately…”
Get full text

How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential by KRAYNOV, Eugenia, MARTIN, Steven W, AWWAD, Michel, WANG, Diane, HURST, Susan, FAHMI, Odette A, DOWTY, Martin, CRONENBERGER, Carol, LOI, Cho-Ming, KUANG, Bing, FIELDS, Owen, FOUNTAIN, Scott

“…Increasing use of therapeutic proteins (TPs) in polypharmacy settings calls for more in-depth understanding of the biological interactions that can lead to…”
Get full text

The time to move cytochrome p450 induction into mainstream pharmacology is long overdue by Smith, Dennis A, Dickins, Maurice, Fahmi, Odette A, Iwasaki, Kazuhide, Lee, Caroline, Obach, R Scott, Padbury, Guy, De Morais, Sonia M, Ripp, Sharon L, Stevens, Jeff, Voorman, Richard, Youdim, Kuresh

Get full text